Overview

Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox

Status:
Completed

Trial end date:
2015-08-01

Target enrollment:
0

Participant gender:
All

Summary

Thalassemia Major patients developed Iron Overload due to blood transfusions and intestinal iron absorption. Renal function caused by Iron overload was studied in a previous study and shows principally tubular disfunction. In this previous study the Iron chelator used was Deferrioxamine. In the last five years an oral Iron chelator was introduced and approved by the FDA, Deferasirox, (Novartis, Switzerland and USA). The purpose of this study is to assess the renal function in Thalassemia Major patients treated with this new oral iron chelator and compare the results with our previous study.

Accepts Healthy Volunteers?

Details

Lead Sponsor:

HaEmek Medical Center, Israel

Treatments:

Chelating Agents
Deferasirox

Criteria

Inclusion Criteria:

- Patients with Thalassemia Major or Intermedia treated by Iron chelators or by blood
transfusions without treatment with iron chelators

Exclusion criteria:

None relevant